NZ736735B2 - A method of in vivo treatment - Google Patents
A method of in vivo treatment Download PDFInfo
- Publication number
- NZ736735B2 NZ736735B2 NZ736735A NZ73673515A NZ736735B2 NZ 736735 B2 NZ736735 B2 NZ 736735B2 NZ 736735 A NZ736735 A NZ 736735A NZ 73673515 A NZ73673515 A NZ 73673515A NZ 736735 B2 NZ736735 B2 NZ 736735B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- defensin
- infection
- amino acid
- plant
- Prior art date
Links
- 108060002187 Def1 Proteins 0.000 claims abstract description 154
- 201000009910 diseases by infectious agent Diseases 0.000 claims abstract description 88
- 210000001519 tissues Anatomy 0.000 claims abstract description 35
- 244000005700 microbiome Species 0.000 claims abstract description 30
- 230000000069 prophylaxis Effects 0.000 claims abstract description 15
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 62
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 49
- 235000004279 alanine Nutrition 0.000 claims description 36
- 230000000813 microbial Effects 0.000 claims description 35
- 230000002401 inhibitory effect Effects 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 15
- 210000003491 Skin Anatomy 0.000 claims description 13
- 239000004599 antimicrobial Substances 0.000 claims description 13
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 12
- 206010007134 Candida infection Diseases 0.000 claims description 9
- 238000007920 subcutaneous administration Methods 0.000 claims description 9
- 230000000699 topical Effects 0.000 claims description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 5
- 208000007027 Oral Candidiasis Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241000287411 Turdidae Species 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims 4
- 238000000576 coating method Methods 0.000 claims 4
- 150000002500 ions Chemical class 0.000 abstract description 17
- 241000233866 Fungi Species 0.000 abstract description 12
- 239000012528 membrane Substances 0.000 abstract description 11
- 241000894006 Bacteria Species 0.000 abstract description 6
- 241000196324 Embryophyta Species 0.000 description 58
- 102000000541 Defensins Human genes 0.000 description 57
- 108010002069 Defensins Proteins 0.000 description 57
- 235000018102 proteins Nutrition 0.000 description 55
- 102000004169 proteins and genes Human genes 0.000 description 55
- 108090000623 proteins and genes Proteins 0.000 description 55
- 235000001014 amino acid Nutrition 0.000 description 39
- 239000000203 mixture Substances 0.000 description 39
- 150000001413 amino acids Chemical class 0.000 description 38
- 230000000694 effects Effects 0.000 description 23
- 239000003795 chemical substances by application Substances 0.000 description 22
- 210000004027 cells Anatomy 0.000 description 19
- 229940024606 Amino Acids Drugs 0.000 description 18
- 229940019746 Antifibrinolytic amino acids Drugs 0.000 description 18
- 241000222122 Candida albicans Species 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 230000001717 pathogenic Effects 0.000 description 12
- 210000004215 spores Anatomy 0.000 description 11
- 210000004379 Membranes Anatomy 0.000 description 10
- 241000223229 Trichophyton rubrum Species 0.000 description 10
- 229940079593 drugs Drugs 0.000 description 10
- 244000052769 pathogens Species 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 230000002538 fungal Effects 0.000 description 9
- 200000000019 wound Diseases 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000003115 biocidal Effects 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000006011 modification reaction Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 206010003486 Aspergillus infection Diseases 0.000 description 7
- 235000014469 Bacillus subtilis Nutrition 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 201000002909 aspergillosis Diseases 0.000 description 7
- 201000007336 cryptococcosis Diseases 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000002609 media Substances 0.000 description 7
- 230000003287 optical Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 241000228245 Aspergillus niger Species 0.000 description 6
- APKFDSVGJQXUKY-INPOYWNPSA-N BRL-49594 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 6
- 206010042938 Systemic candida Diseases 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 229960003942 amphotericin B Drugs 0.000 description 6
- 201000003984 candidiasis Diseases 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000003641 microbiacidal Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 239000001965 potato dextrose agar Substances 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 5
- 108091005771 Peptidases Proteins 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 230000000843 anti-fungal Effects 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- -1 coatings Substances 0.000 description 5
- 244000053095 fungal pathogens Species 0.000 description 5
- 201000002563 histoplasmosis Diseases 0.000 description 5
- 230000001264 neutralization Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000019833 protease Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000228212 Aspergillus Species 0.000 description 4
- 241001225321 Aspergillus fumigatus Species 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 240000008923 Camelina sativa Species 0.000 description 4
- 241000222178 Candida tropicalis Species 0.000 description 4
- 241001522864 Cryptococcus gattii VGI Species 0.000 description 4
- 241000221204 Cryptococcus neoformans Species 0.000 description 4
- 102000033147 ERVK-25 Human genes 0.000 description 4
- 206010017533 Fungal infection Diseases 0.000 description 4
- 241000235058 Komagataella pastoris Species 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 241000893974 Nannizzia fulva Species 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 206010040872 Skin infection Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000000845 anti-microbial Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000002829 reduced Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Chemical compound [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 3
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 3
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 3
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 3
- 241001480043 Arthrodermataceae Species 0.000 description 3
- 229960005261 Aspartic Acid Drugs 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 208000005577 Gastroenteritis Diseases 0.000 description 3
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 3
- 210000004209 Hair Anatomy 0.000 description 3
- 241000229754 Iva xanthiifolia Species 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 210000000282 Nails Anatomy 0.000 description 3
- 241000283898 Ovis Species 0.000 description 3
- 206010064458 Penicilliosis Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010057190 Respiratory tract infection Diseases 0.000 description 3
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 3
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 3
- 241000223238 Trichophyton Species 0.000 description 3
- 230000000996 additive Effects 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 230000001580 bacterial Effects 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 230000037304 dermatophytes Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 229960000555 fenyramidol Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229940079866 intestinal antibiotics Drugs 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 210000004962 mammalian cells Anatomy 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 3
- 230000000241 respiratory Effects 0.000 description 3
- 231100000486 side effect Toxicity 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- VHVPQPYKVGDNFY-TUJWMRSMSA-N 2-[(2S)-butan-2-yl]-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-TUJWMRSMSA-N 0.000 description 2
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 210000001367 Arteries Anatomy 0.000 description 2
- 229960001230 Asparagine Drugs 0.000 description 2
- 241000228197 Aspergillus flavus Species 0.000 description 2
- 229940091771 Aspergillus fumigatus Drugs 0.000 description 2
- 241001465318 Aspergillus terreus Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N Bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 2
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 2
- 102100015581 CAMP Human genes 0.000 description 2
- 108060006634 CAMP Proteins 0.000 description 2
- 229940095731 Candida albicans Drugs 0.000 description 2
- 208000006081 Cryptococcal Meningitis Diseases 0.000 description 2
- 210000002472 Endoplasmic Reticulum Anatomy 0.000 description 2
- 210000003743 Erythrocytes Anatomy 0.000 description 2
- ZEAJXCPGHPJVNP-UHFFFAOYSA-N Fenyramidol Chemical compound C=1C=CC=CC=1C(O)CNC1=CC=CC=N1 ZEAJXCPGHPJVNP-UHFFFAOYSA-N 0.000 description 2
- 241000223218 Fusarium Species 0.000 description 2
- 229960002743 Glutamine Drugs 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 206010019233 Headache Diseases 0.000 description 2
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- DDFOUSQFMYRUQK-RCDICMHDSA-N Isavuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC=C(F)C=2)F)=NC=1C1=CC=C(C#N)C=C1 DDFOUSQFMYRUQK-RCDICMHDSA-N 0.000 description 2
- 229960000788 Isavuconazole Drugs 0.000 description 2
- 206010023332 Keratitis Diseases 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 241000555676 Malassezia Species 0.000 description 2
- 206010027209 Meningitis cryptococcal Diseases 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-Bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 241000208125 Nicotiana Species 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 241000233654 Oomycetes Species 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 241001671294 Picramnia Species 0.000 description 2
- 208000008666 Pythiosis Diseases 0.000 description 2
- 210000003324 RBC Anatomy 0.000 description 2
- 241000235527 Rhizopus Species 0.000 description 2
- 240000005384 Rhizopus oryzae Species 0.000 description 2
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 2
- 206010040490 Sexually transmitted disease Diseases 0.000 description 2
- 241001459572 Trichophyton interdigitale Species 0.000 description 2
- 240000008529 Triticum aestivum Species 0.000 description 2
- 206010046577 Urinary tract infection Diseases 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000007244 Zea mays Nutrition 0.000 description 2
- 206010061418 Zygomycosis Diseases 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 229960004130 itraconazole Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000009906 meningitis Diseases 0.000 description 2
- 230000003278 mimic Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 201000007524 mucormycosis Diseases 0.000 description 2
- 101700071116 nac-3 Proteins 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000012449 sabouraud dextrose agar Substances 0.000 description 2
- 101710004799 sm-amp-x Proteins 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960005486 vaccines Drugs 0.000 description 2
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2S)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical class OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-Trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- KFDPCYZHENQOBV-UHFFFAOYSA-N 2-(bromomethyl)-4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1CBr KFDPCYZHENQOBV-UHFFFAOYSA-N 0.000 description 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
- UHMARZNHEMRXQH-UHFFFAOYSA-N 3a,4,5,7a-tetrahydro-2-benzofuran-1,3-dione Chemical compound C1=CCCC2C(=O)OC(=O)C21 UHMARZNHEMRXQH-UHFFFAOYSA-N 0.000 description 1
- YFZOUMNUDGGHIW-UHFFFAOYSA-M 4-Chloromercuribenzoic acid Chemical compound OC(=O)C1=CC=C([Hg]Cl)C=C1 YFZOUMNUDGGHIW-UHFFFAOYSA-M 0.000 description 1
- JAJQQUQHMLWDFB-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-5-phenylpentanoate Chemical compound OC(=O)CC(O)C(N)CC1=CC=CC=C1 JAJQQUQHMLWDFB-UHFFFAOYSA-N 0.000 description 1
- DFVFTMTWCUHJBL-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-6-methylheptanoate Chemical compound CC(C)CC(N)C(O)CC(O)=O DFVFTMTWCUHJBL-UHFFFAOYSA-N 0.000 description 1
- AVFIYMSJDDGDBQ-UHFFFAOYSA-N 7-methyl-3-methylidene-6-(3-oxobutyl)-4,7,8,8a-tetrahydro-3aH-cyclohepta[b]furan-2-one Chemical class C1C=C(CCC(C)=O)C(C)CC2OC(=O)C(=C)C21 AVFIYMSJDDGDBQ-UHFFFAOYSA-N 0.000 description 1
- 206010000269 Abscess Diseases 0.000 description 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229940093740 Amino acids and derivatives Drugs 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N Aminocaproic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 208000007502 Anemia Diseases 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 241000293034 Apophysomyces elegans Species 0.000 description 1
- 240000000127 Arcangelisia flava Species 0.000 description 1
- 241000582025 Aspergillus felis Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 240000008371 Bacillus subtilis Species 0.000 description 1
- 229940075615 Bacillus subtilis Drugs 0.000 description 1
- 206010060945 Bacterial infection Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 206010005098 Blastomycosis Diseases 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 206010006473 Bronchopulmonary aspergillosis Diseases 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000283708 Capra aegagrus Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 241000293020 Cokeromyces recurvatus Species 0.000 description 1
- 229920000453 Consensus sequence Polymers 0.000 description 1
- 241001125840 Coryphaenidae Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000293018 Cunninghamella bertholletiae Species 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- XVOYSCVBGLVSOL-UHFFFAOYSA-N Cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 241000157286 Dahlia merckii Species 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N Diethylpyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 229940096118 Ella Drugs 0.000 description 1
- 241001480036 Epidermophyton floccosum Species 0.000 description 1
- 210000000981 Epithelium Anatomy 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N Ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N Fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N Flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 241000223221 Fusarium oxysporum Species 0.000 description 1
- 241000427940 Fusarium solani Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- JZDHUJAFXGNDSB-WHFBIAKZSA-N Glu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O JZDHUJAFXGNDSB-WHFBIAKZSA-N 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N Glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 1
- 229940015043 Glyoxal Drugs 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 206010020144 Histoplasmosis disseminated Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 241000692870 Inachis io Species 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N Iodoacetic acid Chemical class OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 101700059121 KEX2 Proteins 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N Ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-2-aminohexanoic acid zwitterion Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid zwitterion Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241000428512 Malassezia dermatis Species 0.000 description 1
- 241000555688 Malassezia furfur Species 0.000 description 1
- 241001291477 Malassezia restricta Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241000235388 Mucorales Species 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000818707 Nannizzia incurvata Species 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N Natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 229960003255 Natamycin Drugs 0.000 description 1
- 241001139967 Neoscytalidium Species 0.000 description 1
- 240000002142 Nicotiana alata Species 0.000 description 1
- FBTSQILOGYXGMD-LURJTMIESA-N Nitrotyrosine Chemical class OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 description 1
- 150000007930 O-acyl isoureas Chemical class 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 229960003104 Ornithine Drugs 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010067565 Pneumonia cryptococcal Diseases 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 208000004430 Pulmonary Aspergillosis Diseases 0.000 description 1
- 229960001327 Pyridoxal Phosphate Drugs 0.000 description 1
- 241000197220 Pythium insidiosum Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000235525 Rhizomucor pusillus Species 0.000 description 1
- 241000293025 Saksenaea vasiformis Species 0.000 description 1
- 229940043230 Sarcosine Drugs 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241000122799 Scopulariopsis Species 0.000 description 1
- 241000223255 Scytalidium Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040882 Skin lesion Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- RINCXYDBBGOEEQ-UHFFFAOYSA-N Succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000736855 Syncephalastrum racemosum Species 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 241001480048 Trichophyton tonsurans Species 0.000 description 1
- 241001480050 Trichophyton violaceum Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 241001238303 Turdus fuscater Species 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 206010062910 Vascular infection Diseases 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000009632 agar plate Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000001588 bifunctional Effects 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 200000000017 bloodstream infection Diseases 0.000 description 1
- 239000007469 bmm - medium Substances 0.000 description 1
- 201000004813 bronchopneumonia Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- AWGTVRDHKJQFAX-UHFFFAOYSA-M chloro(phenyl)mercury Chemical compound Cl[Hg]C1=CC=CC=C1 AWGTVRDHKJQFAX-UHFFFAOYSA-M 0.000 description 1
- VIMWCINSBRXAQH-UHFFFAOYSA-M chloro-(2-hydroxy-5-nitrophenyl)mercury Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[Hg]Cl VIMWCINSBRXAQH-UHFFFAOYSA-M 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000001010 compromised Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000003372 histidine group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002463 imido esters Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- SJFKGZZCMREBQH-UHFFFAOYSA-N methyl ethanimidate Chemical compound COC(C)=N SJFKGZZCMREBQH-UHFFFAOYSA-N 0.000 description 1
- 239000002855 microbicide agent Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 230000002956 necrotizing Effects 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940006093 opthalmologic coloring agents Diagnostic Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000004789 organ systems Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- SCKXCAADGDQQCS-UHFFFAOYSA-N performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 150000004291 polyenes Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000529 probiotic Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine zwitterion Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000224 toxic side effect Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960000200 ulipristal Drugs 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 235000021307 wheat Nutrition 0.000 description 1
- OJUGVDODNPJEEC-UHFFFAOYSA-N α-oxobenzeneacetaldehyde Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-UHFFFAOYSA-N α-phenylglycine Chemical compound OC(=O)C(N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-UHFFFAOYSA-N 0.000 description 1
Abstract
The present disclosure teaches the treatment or prophylaxis of infection by a microorganism including a fungus or bacterium which is infecting or colonizing an in vivo tissue, surface or membrane. The method comprising administering to the subject with the infection or directly to the site of infection a plant-derived defensin or a functional variant or derivative thereof. ion a plant-derived defensin or a functional variant or derivative thereof.
Description
A METHOD OF IN VIV0 TREATMENT
BACKGROUND
FIELD
The present disclosure relates generally to the control of in viva microbial infection
in humans and animals. Agents and natural and synthetic ations and extracts useful
for the control of microbial infection of non—external tissues, surfaces and membranes are
also encompassed by the subject disclosure.
DESCRIPTION OF RELATED ART
Bibliographic s of the ations referred to by author in this specification
are collected etically at the end of the description.
Reference to any prior art in this specification is not, and should not be taken as, an
acknowledgment or any form of tion that this prior art forms part of the common
general knowledge in any y.
Microbial infection can lead to significant health issues in humans and animals.
Examples include fungal and bacterial infection of mucosal tissue, atory es,
wounds and deep tissue.
Although antimicrobial agents including antibiotics and chemical microbicides
have been successful in human and veterinary ne, there is a range of environmental
and regulatory concerns with the continued use of these microbicides for a host of reasons
including the widespread development of resistance. There is clearly a need to develop
alternative mechanisms of controlling infection in humans and animals by microbial
pathogens or at least to complement existing antimicrobial agents.
The most prevelant human fungal pathogen is Candida. Candida is a commensal
organism and part of the normal flora for 30—50% of the population but can cause disease
in patients who are immunocompromised or whose natural microflora is disrupted such as
through the use of antibiotics. Several species of Candida can cause infections in humans
ing Canida albicans, C. glabrata, C parasilosis, C. tropicalis and C. .
Common Candida infections include infections of the mucosal membranes such as oral
and vaginal thrush. Oral candidiasis (oropharyngeal) is one of the most common infections
observed in those suffering HIV (Singh et al. (2014) Journal of Oral and Maxillofacial
Pathology 18(Supp1):SSl—SSS). More serious Candida infections include systemic blood
stream infections (Candidemia) and biofilms on implanted medical devices. Candidemia is
responsible for between 2 and 8 of every 1000 hospital intensive care admissions and has a
—day mortality rate of ~30%. Candidemia is terised by spreading of Candida cells
to the entire body creating abscesses in almost all vital organs, inducing their failure and
g to a morbidity rate of 50%. Antifungal agents belonging to the e, azole and
echinocandin family have been used to treat Candidiasis, however, all have unwanted side
effects such as toxicity, drug—drug interactions and resistance. Candidiasis is commonly
observed in animals and often caused by C. albicans. Although C. albicans is a normal
inhabitant of animal species, it can be an opportunistic en. Birds are most commonly
affected. Superficial infections have been described in pigs and foals. Systemic candidiasis
has been observed in cattle, calves, sheep and foals following prolonged re to
antibiotics.
Another serious fungal infection is illosis. Aspergillosis comprises a large
spectrum of fungal es caused by Aspergillus that primarily affect the lungs, although
other organ systems can be ed. Clinical manifestations of lung aspergillosis are
ic bronchopulmonary aspergillosis, chronic necrotizing aspergillosis, illoma
and the most severe, ve aspergillosis (IA). IA is the most common filamentous
fungal infection in immunocompromised patients (Patterson et al. (2000) Medicine
79(4):250—60). The genus Aspergillus includes over 185 species, which are ubiquitous in
nature, especially common in soil and decaying vegetation. The most common ens
that cause disease in humans are A.fumigatus, A. flavas, A. terreas, A. niger and A
tabingensis. Reports have shown that attributable ity of IA exceeds 80% (Fisher et
al. (1981) The American Journal of Medicine 7](4):571—7). Current treatments involve
members of polyene and azole family, including amphotericin b and isavuconazole
respectively. These treatments display unwanted side effects such as toxicity, drug—drug
interactions and for isavuconazole, the mortality rate remains at 18%. Aspergillosis is also
a common fungal ion observed in s. It is caused by several Aspergillas species
such as A. fumigatus, A. terreus, A. niger, A. nidulans, A. viridnutans, A. flavus and A. felis.
Animals that are affected include birds, , dogs, cats and .
Cryptococcosis is another ious disease caused by fungal pathogens. The
manifestation may range from asymptomatic to mild bronchopneumonia to life—threatening
infections of the central s system (CNS; Mitchell & Perfect (1995) Clinical
Microbiology Reviews 8(4):515—48). Furthermore, cryptococcal itis is one of the
most widely observed infections in patients suffering from AIDS (Vibhagool et al. (2003)
Clinical Infectious Diseases 36(10):1329—31). The major causative agents of
cryptococcosis are from the Cryptococcas family, generally C. neoformans and C. gatti.
The most serious type of cryptococcal disease arises from uncontrolled pulmonary
cryptococcosis, which sses to cryptococcal meningitis. This progression tends only
to occur in patients that are immunosuppressed. The most common treatment for
cryptococcal meningitis is ericin B in combination with flucytosine. Early
appropriate treatment has reduced the mortality rate from 14—25% to 6%, however, toxic
side effects from amphotericin B are common including hypotension, anorexia, vomiting,
headache and multiple organ damage. Cryptococcosis is also ed in s. It is
most common in cats but has also been reported in dogs, cattle, horses, sheep, goats, birds
and wild animals. Transmission occurs via inhalation of spores or by contamination of
wounds.
Penicilliosis is another common opportunistic infection in patients with HIV and
9.36% of patients with HIV develop Penicilliosis. The causative pathogen of penicilliosis
is Penicilliam marnefi‘ei (also known as myces marnefi‘ei). AIDS patients suffering
from P. marnefi‘ei infection display symptoms of fever, anaemia, weight loss,
lymphadenopathy, respiratory signs and skin lesions. The mortality for those that do not
undergo treatment is at least 75% (Supparatpinyo et al. (1996) Lancet 15): 1 10—3).
Murcomycoses are the second most frequent mold infections observed in
immunosuppressed patients. Most mucormycoses are life threatening and the most
WO 91790
common presentation is severe ion of the sinuses, which may extend to the brain.
Infectious agents belong to the order Mucorales with the most recognized causative agent
belonging to the Genus Rhizopus (Rhizopus oryzae). However, additional mucormycosis
causing species have been identified including Apophysomyces elegans, Cunninghamella
bertholletiae, Saksenaea vasiformis, Rhizomucor pusillus, Syncephalastrum racemosum,
Cokeromyces recurvatus, mucor elegans (Gomes et al. (2011) Clinical
Microbiology Reviews 24(2):4ll—45). The mortality rates are very high between 40% and
85%. The cutaneous forms of the infection represent the lowest mortality rate at 15% with
the disseminated disease carrying a mortality rate approaching 100%. Treatments currently
e amphotericin B, surgical procedures and azole treatments such as posaconazole.
Pythiosis is an emerging, life threatening infectious disease. It commonly affects
horses and has been found in other s such as dogs, cats and cattle causing
granulomatous ions in the skin, intestines and arteries (Wanachiwanawin et al.
(2004) Vaccine 22(27-28):3613—21). The first report of a human infection was reported in
Thailand in 1985 and has since been reported in tropical and subtropical countries. The
disease can manifest as a localized form, including eye infections, corneal ulcers with
cutaneous or aneous involvement. However, it can also present as a systemic or
vascular infection and this is usually the most severe (Thianprasit et al. (1996) t
Topics in Medical Mycology 7(1):43—54). Clinical features are limb ischemia and gangrene
and if the infection reaches a main artery, the patient will often die from systemic
pythiosis. The major pathogen is Pythium insidiosum, a fungus—like aquatic organism from
the phylum Oomycota. ngal ents such as amphotericin B and various azoles
display poor efficacy for systemic and ar phythiosis and the most effective ent
is considered to be amputation of the site of ion.
Mycotic keratitis has been reported in many parts of the world, particularly tropical
areas. There are two major forms, one caused by filamentous fungi such as Fnsarium and
Aspergillus and another form caused by yeast—like pathogens such as Candida. Traumatic
injury is a major predisposing factor for keratitis caused by filamentous fungi. The major
filamentous fungal species involved are F. , F. oxysporum, A fumigatus and A flavus
(Thomas (2003) Eye (London, England) I7(8):853—62). Topical natamycin and
amphotericin B are used as a first line of ent, however if deep lesions are present
oral ketoconazole, itraconazole or fluconazole may be administered with reasonable
response rates (Thomas (2003) . In cases where medical treatments fail, surgical
intervention may be necessary.
Histoplasmosis is a fungal infection that contracted after inhalation of the spores of
the thermally dimorphic fungus Histoplasmosis capsulatum. This pathogen is found in
North America, South America, Africa and Asia. There are several types of
histoplasmosis, with the mildest form producing little or any symptoms at all. However,
infants or those with compromised immune systems may develop progressive disseminated
histoplasmosis, which can be fatal if left untreated (Wheat et al. (1990) Medicine
69(6):36l—74). Symptoms include fever, chills, headache, muscle aches and a dry cough.
For severe infections, amphotericin B is recommended for l — 2 weeks followed by
itraconazole. ericin B displays very high, some , levels of ty.
Histoplasmosis has also been described in many animal species, however infection
is rare in dogs and cats. Infection usually arises following aerosol exposure to the
respiratory tract.
Blastomycosis is caused by the dimorphic fungus Blastomyces dermatitidis.
Infection is most common among dogs and cats but it has also been ed in horses,
ferrets, wolves, deer, lions and dolphins. It is limited to North a and transmission is
thought to be via tion of aerosolised conidia.
Plant defensins are small (45—54 amino acids), basic proteins with four to five
disulfide bonds (Janssen et al. (2003) Biochemistry 42(27):82l4—8222). They share a
common ide bonding pattern and a common structural fold, in which a triple—
stranded, antiparallel B—sheet is tethered to an d—helix by three disulfide bonds, g a
cysteine—stabilized dB motif. A fourth disulfide bond also joins the N— and C—termini
leading to an extremely stable structure. A variety of functions has been uted to
defensins, including anti—bacterial activity, protein synthesis inhibition and oc—amylase and
protease inhibition (Colilla et al. (1990) FEBS Lett 270(1-2): 191— 194; Bloch and
Richardson (1991) FEBS Lett 279(1): 101—104), generally in the context of plants.
The structure of defensins consists of seven 'loops', defined as the regions between
cysteine residues. Loop 1 encompasses the first B—strand (1A) as well as most of the
flexible region that connects this B—strand to the d—helix (1B) between the first two
ant cysteine residues. Loops 2, 3 and the beginning of 4 (4A) make up the d—helix,
while the remaining loops (4B — 7) make up B—strands 2 and 3 and the flexible region that
connects them rpin region) (van der Weerden et al. (2013) Cell Mol Life Sci 70 (19):
3545—3570). Loop 5 of the plant defensins is known to be essential for antifungal activity
and an important determinant for mechanism of action of these proteins (Sagaram et al.,
(2011) PLoS One 6.4: ).
Plant defensins lly share eight completely ved ne residues.
These es are commonly referred to as “invariant cysteine residues”, as their
presence, location and connectivity are conserved amongst defensins. Based on sequence
similarity, plant defensins can be categorized into different groups. Within each group,
sequence homology is relatively high whereas inter—group amino acid similarity is low
(van der Weerden et al. (2013) Fungal Biol Rev 26:121—131). Plant defensins belonging to
different groups generally have different biological activities or different mechanisms of
action for the same biological activity.
There are two major classes of plant defensins. Class I defensins consist of an
endoplasmic reticulum (ER) signal sequence followed by a mature defensin domain. Class
II defensins are produced as larger precursors with C—terminal pro—domains or pro—peptides
(CTPPs) of about 33 amino acids. Most of the Class II defensins fied to date have
been found in Solanaceous plant species.
There is a need to p protocols to more effectively manage microbial
infection in humans and animals. Whilst some defensins have antifungal ties, their
activities across different fungal pathogens vary significantly and the majority of
demonstrated activity has been toward plant fungal pathogens.
SUMMARY
Amino acid sequences are referred to by a sequence identifier number (SEQ ID
NO). The SEQ ID NOs correspond numerically to the sequence identifiers <400>l (SEQ
ID NOzl), <400>2 (SEQ ID NO:2), etc. A y of the sequence identifiers is ed
in Table l. A sequence listing is provided after the claims.
The present disclosure teaches a method for inhibiting infection by a
rganism in in viva tissue in a subject the method comprising contacting the in vivo
tissue with an effective amount of a plant defensin or a functional natural or synthetic
derivative or variant thereof, the plant defensin, derivative or variant selected from the list
consisting of SEQ ID NO:1 through 47 or a plant defensin having at least about 80%
amino acid sequence similarity to any one of SEQ ID NO:1 through 47 after l
alignment for a time and under conditions sufficient to eradicate or otherwise l
microbial growth or colonization. Despite evolving to target plant pathogens, the plant
defensins d herein have potent activity t rganism with no or medically
acceptable minimal off target ty on ian cells. More surprisingly, many of the
defensins have a microbicidal activity on contact.
The defensins defined by SEQ ID NO:1 through 47 are defined in Tables 1 and 2.
The present invention encompasses the treatment of any internal surface tissue or
membrane which is not external skin, hair or nails. In an embodiment, the defensin is
defined by the consensus amino acid sequence SEQ ID NO:24 or a functional natural or
synthetic derivative or variant thereof which includes a defensin having at least 80%
similarity to SEQ ID NO: 24 after optimal alignment wherein SEQ ID NO:24 has an
optional N—terminal alanine residue. Examples include SEQ ID NO:1, SEQ ID NO:2 and
SEQ ID NO:3 and their variants with an N—terminal alanine residue (SEQ ID NO: 25
though 27, respectively). Reference to "external skin" does not exclude subcutaneous
layers of external skin or a e wound.
Examples of microbial infection include infection by fungi and bacteria. These
include ions by Candida such as of mucosal membranes (e.g. thrush), the
gastrointestinal tract and the blood stream, infections by Cryptococcus such as meningitis,
infections by Aspergillus such as respiratory ions, subcutaneous infections such as
mucorymycosis, bacterial gastroenteritis, respiratory ion, wound ion and
ion leading to a sexually transmitted disease. Also included are infections by Ecoli,
such as diarrhoea and urinary tract infections and by Bacillus spp. such as ear ions,
meningitis, urinary tract infections and septicaemia.
The defensins contemplated for use in the treatment protocol are defined by the
amino acid sequence selected from SEQ ID NO:l through 47 listed in Table l and further
characterized in Table 2 as well as a defensin having at least 80% similarity to any one of
the SEQ ID NO:l through 47 after optimal alignment. For the sake of brevity, reference to
“SEQ ID NO:l through 47” hereinafter includes defensins having at least 80% similarity to
any one of SEQ ID NO:l through 47. In an embodiment, the defensin is a permeabilizing
defensin or a functional l or synthetic derivative or variant thereof. Examples of
synthetic ts include where a LooplB from a Class I defensin replaces the LooplB
from the Solanaceous Class II defensin. These include HXP4, HXP34 and HXP35. Other
variants or derivatives include a defensin listed in Table 2 or having at lest 80% similarity
to a defensin listed in Table 2 wherein the defensin ses an alanine residue at its N—
terminus (i.e. SEQ ID NO:25 h 47). The addition of an alanine at the N—terminus of
a defensin allows the peptide to be produced recombinantly in the Pichia pastoris
expression system without the need for the STEl3 protease site. The STEl3 site normally
allows for efficient proessing of the 0t—mating factor secretion signal by KEX2. However,
under high expression loads the STEl3 protease cleavage can be inefficient g to Glu—
Ala s remaining on the N—terminus of the peptide. The additional negative charge
red by these s can be detrimental to the activity of plant defensins. The STEl3
protease site can be ed with an alanine to prevent incomplete processing (Cabral er
al., (2003) Protein Expres Purif 3](]):llS—l22). The presence of an N—terminal alanine
can also decrease the ability of the defensin to lyse red blood cells (WO201 1/ 16074).
In an embodiment, a defensin listed in Table 2 (SEQ ID NO:l through 47) is
modified to enhance the stability of the peptide. In a further embodiment this is achieved
by replacing amino acids that are susceptible to deamidation such as asparagine and
glutamine, or amino acids that are susceptible to isomerization such as aspartic acid, with
amino acids that are not susceptible to cations. In a particular embodiment, the
defensins HXLOOS, HXL035 or HXL036 are modified at positions 18, 36 or 42.
In an embodiment, a defensin listed in Table 2 (SEQ ID NO:1 through 47) is
modified to se the positive charge of the peptide. Positive charge is known to be
important for the ty of antimicrobial es, including plant defensins am er
al., (2011) PLoS One 6.4: ). In an embodiment the increase in positive charge is
achieved by replacement of a negatively charged residue such as glutamatic acid or
ic acid with a neutral amino acid. In a preferred embodiment the l amino acid
is an alanine or a glycine. In another embodiment, the increase in positive charge is
achieved by replacing a neutral amino acid with a positively charged residue such as lysine
or arginine.
In an embodiment, the treatment es a defensin in combination with a non—
defensin peptide, a proteinase inhibitor, another defensin or a proteinaceous or non—
proteinaceous (i.e. chemical) icide including an antibiotic.
In an embodiment, the defensin is provided by any means including by oral,
inhalation, intravenous, sublingual, intraperitoneal, rectal or subcutaneous administration.
Alternatively, it is topically applied to an internal tissue, surface or membrane or to a
wound. The defensin can also be administered via a slow release patch or implant (e.g. a
subcutaneous implant). The defensins can also be coated on the surface of medical devices
such as catheters and ts or condoms or other sheaths.
Further taught herein is a formulation or extract comprising a plant defensin
selected from SEQ ID NO:1 h 47. The formulation or t may further comprise
another active agent or a combination of formulations or extracts wherein at least one
formulation or extract comprises a defensin as defined herein which are admixed prior to
use or used sequentially in either order. The plant defensins or extracts comprising same as
defined herein may be used such as in the form of systemic or local formulations, coatings,
gels, ointments, cream, spray, foam, capsule, tablet, oral formulations, inhalable or
atomized formulations and the like ing herbal formulations and plant extracts.
Enabled herein is a use of a plant defensin as defined by SEQ ID NO:1 through 47
in the manufacture of a medicament for the treatment or prophylaxis of microbial infection
of in vivo tissue in a subject. Also taught herein is a plant defensin as defined by SEQ ID
NO:1 through 47 for use in the treatment or laxis of microbial infection of in vivo
tissue in a subject. Further taught herein is a plant defensin as d by SEQ ID NO:1
through 47 When used in the treatment of microbial infection of in vivo tissue in a subject.
In an ment, the defensin has no adverse ty or medically able minimal
activity against mammalian cells. Activity against mammalian cells will increase the
likelihood of dermal irritation and other side effects.
As indicated above, the in may also be a onal natural or synthetic
derivative or variant of a defensin as defined by any one of SEQ ID NO: 1 through 47.
The subject may be a human or non—human animal subject.
Further contemplated herein is an isolated microorganism engineered to express a
in as defined herein for use in the manufacture of compositions comprising the
microorganisms. In an embodiment, the microorganism is a yeast such as but not limited
to Pichia. Such compositions are useful in the treatment of humans and animals such as in
the form of a probiotic. Alternatively, the in is provided as a cell extract including a
plant extract or microbial extract.
A kit in compartmental form comprising a plant defensin or a functional natural or
synthetic derivative or variant thereof, the plant defensin selected from the list consisting
of SEQ ID NO:1 through 47, is also taught herein. In an optional embodiment, another
compartment comprises a second active agent and optionally bly in a further
compartment or together in an existing compartment, a pharmaceutically or veterinarily
acceptable diluent, carrier or excipient. In an embodiment, the defensin is defined by the
consensus amino acid sequence set forth in SEQ ID NO: 24. Examples include HXLOOS
(SEQ ID NO: I), HXL035 (SEQ ID NO: 2), HXL036 (SEQ ID NO: 3) and the N—terminal
alanine forms, SEQ ID NO: 25 though 27, respectively.
In an ment, a defensin contemplated for use herein may or may not
comprise an N—terminal e residue. This is particularly the case with some
recombinant defensins which comprise the N—terminal alanine e. Encompassed by
the definition of a "defensin" herein is any of SEQ ID NO:1 though 23 with an N—terminal
alanine. These are ented as SEQ ID NO:25 through 47. The consensus amino acid
sequence, SEQ ID NO: 24, has an al N—terminal alanine residue.
The addition of an alanine at the N—terminal of a defensin allows the peptide to be
produced predominantly in Pichia pastoris expression system without need for the STEl3
se site. (Cabral er al. (2003) Protein Express Purif 3](]):llS—l22). The presence of
the N—terminal alanine can also decrease the ability of a in to lysine red blood cells.
In an embodiment, a defensin listed in Table 2 (SEQ ID NO:1 through 47) is
modified to enhance the stability of the peptide. In a r embodiment, this is achieved
by replacing amino acids that are susceptible to deamidation such as asparagine and
glutamine, or amino acids that are susceptible to isomerization such as aspartic acid, with
amino acids that are not susceptible to modifications. In a particular embodiment, the
defensins HXLOOS, HXL035 or HXL036 are modified at positions 18, 36 or 42.
In an ment, a defensin listed in Table 2 (SEQ ID NO:1 h 47) is
modified to increase the positive charge of the peptide. Positive charge is known to be
important for the ty of antimicrobial peptides, including plant defensins. In an
embodiment the increase in positive charge is achieved by replacement of a negatively
d residue such as glutamatic acid or aspartic acid with a neutral amino acid. In an
embodiment, the neutral amino acid is an alanine or a glycine. In another embodiment, the
increase in positive charge is achieved by replacing a neutral amino acid with a positively
d residue such as lysine or arginine
Conservative amino acid changes are also contemplated herein.
Table 1
Summary ence identifiers
SEQUENCE
DESCRIPTION
ID NO:
_—Amino acid sequence of HXLOOS protein
_—Amino acid sequence of HXL035 protein
_—Amino acid sequence of HXL036 protein
_—Amino acid sequence of HXL001 protein
_—Amino acid sequence of HXL002 protein
Amino acid sequence of HXL003 protein
_—Amino acid sequence of HXL004 protein
Amino acid ce of HXLOOS protein
Amino acid ce of HXL009 protein
>—‘ 0 Amino acid sequence of HXL012 protein
_—Amino acid sequence of HXL013 protein
t—‘ l\) Amino acid sequence of HXL015 protein
_—Amino acid sequence of HXL032 protein
y—A 4; Amino acid ce of HXL033 protein
>—‘ L1] Amino acid sequence of HXL034 protein
>—‘ O’\ Amino acid sequence of Nle n
>—‘ \1 Amino acid sequence of NsD2 protein
>—‘ 00 Amino acid sequence of NaDl protein
>—‘ \0 Amino acid sequence of NoD173 protein
l\)0 Amino acid sequence of DmAMPl protein
l\) >—‘ Amino acid ce of HXP4 protein
l\)l\) Amino acid sequence of HXP34 protein
l\) U) Amino acid sequence of HXP35 protein
l\)4; Consensus SCunl’lCC
[\) LII Amino acid sequence of HXLOOS protein + N—terminal alanine
l\) O’\ Amino acid sequence of HXL035 protein + N—terminal alanine
WO 91790
SEQUENCE
DESCRIPTION
ID NO:
l\)\1 Amino acid sequence of HXL036 protein + N—terminal alanine
l\) 00 Amino acid sequence of HXLOOl protein + N—terminal alanine
l\) \0 Amino acid sequence of HXL002 protein + N—terminal alanine
L») 0 Amino acid sequence of HXL003 protein + N—terminal alanine
_—Amino acid sequence of HXL004 protein + N—terminal alanine
U) l\) Amino acid sequence of HXLOOS protein + N—terminal alanine
b) b) Amino acid sequence of HXL009 protein + N—terminal alanine
b) 4; Amino acid sequence of HXL012 n + N—terminal alanine
DJ LII Amino acid sequence of HXLOl3 protein + N—terminal alanine
_—Amino acid sequence of HXLOlS protein + N—terminal alanine
o acid sequence of HXL032 protein + N—terminal alanine
b) 00 Amino acid ce of HXL033 protein + N—terminal alanine
U) \0 Amino acid sequence of HXL034 protein + N—terminal alanine
4;0 Amino acid sequence of Nle protein + N—terminal e
_—4; Amino acid sequence of NsD2 protein + N—terminal alanine
4; l\) Amino acid sequence of NaDl protein + inal alanine
4; b) Amino acid sequence of NoDl73 protein + inal alanine
4;4; Amino acid sequence of DmAMPl protein + N—terminal alanine
4; L11 Amino acid ce of HXP4 protein + N—terminal alanine
4; O’\ Amino acid sequence of HXP34 protein + N—terminal alanine
4;\1 Amino acid sequence of HXP35 protein + N—terminal alanine
Amino acid sequences for HXL proteins are recited in US Patent No. 6,911,577 and
related patent family members.
_ 14 _
Table 2
es ofplant defensins
Type
1 (Class I,
Class II Reference
Pentide Source variant)
HXL008 Picramnia Class I SEQ ID N021
HXL035 Picramm'a Class I SEQ ID NO:2
pentarzdra
HXL036 Picramnia Class I SEQ ID N033
penlandra 1 1
HXLOOI Zea mays l Class I SEQ ID NO:4
HXLOOZ Triticum aestivum Class I g SEQ ID NO:5
1HXL003 Triticum aestiva—C Class I l SEQ ID N016
m'iconana l
Class I SEQ ID NO:7
benthamiana
HXL005 Taraxcum kok- —fiass I SEQ ID N0z8
saghyz
HXL009 Zea mays Class I SEQ ID N029
ITJXL012 Amaranlhus Class I SEQ ID NO:] 0
ret‘rqflexus
HXL013 Glycine max Class I SEQ ID N011]
HXL015 Oryza sativa 3 Class I SEQ ID N0112 ‘
HXL032 Triticum aestivum Class I fSEQ ID N0:l3 1
HXL033 Parthenium Class 1 l SEQ ID NO: 14
argenrarum
HXL034 Nicoliana Class I
1 SEQ ID N0:15
benthamiana
Nle ana Class II SEQ ID NO:16
suaveolens l
RECTIFIED SHEET (RULE 91) ISA/AU
Type
(Class 1,
Class II Reference
Peptide Source variant)
NsD2 Nicotiana Class II SEQ ID NO:l7
suaveolens
NaDl Nicotiana alata Class II SEQ ID N0:18
NOD173 Nicotiana Class II SEQ ID NO:l9
occidentalis spp
DmAMPl Dahlia merckii Class I SEQ ID N020
HXP4 Artificial t SEQ ID N021
HXP34 Artificial Variant SEQ ID N022
HXP35 Artificial Variant SEQ ID N023
Consensus
HXL008 + Ala Artificial Variant SEQ ID N025
HXL035 + Ala Artificial t SEQ ID N026
HXL036 + Ala Artificial Variant SEQ ID N027
HXL001 + Ala Artificial t SEQ ID N028
HXL002 + Ala Artificial Variant SEQ ID N029
HXL003 + Ala Artificial Variant SEQ ID N0:30
HXL004 + Ala Artificial Variant SEQ ID N0:3l
HXL005 + Ala Artificial Variant SEQ ID N0:32
HXL009 + Ala Artificial Variant SEQ ID N0:33
HXL012 + Ala Artificial Variant SEQ ID N0:34
HXL013 + Ala Artificial t SEQ ID N0:35
HXL015 + Ala Artificial Variant SEQ ID N0:36
HXL032 + Ala Artificial Variant SEQ ID N0:37
HXL033+ Ala Artificial Variant SEQ ID N0:38
HXL034 + Ala Artificial Variant SEQ ID N0:39
Nle + Ala Artificial Variant SEQ ID N0:40
2015/050294
—16-
Type
(Class 1,
Class II Reference
Peptide Source variant)
SEQ ID NO:41
SEQ ID NO:42
N0D173 +Ala Variant SEQ ID NO:43
DmAMPl + Artificial Variant SEQ ID NO:44
SEQ ID NO:45
HXP34 + Ala Variant SEQ ID NO:46
HXP35 + Ala Variant SEQ ID NO:47
BRIEF DESCRIPTION OF THE FIGURES
s 1(a) through (e) are representations of alignments of amino acids of the
various defensins encompassed herein. .
Figures 2(a) through (d) are graphical representations showing the effect of the
plant defensins NaDl (dashed line) and HXLOOS (solid line) on the growth of four clinical
isolates of Trichophyton rubrum in vitro. Fungal growth was measured by the increase in
l density at 595 nm (A595) achieved 72 hours after inoculation of the growth
medium and is plotted as a percentage of growth relative to a no—protein control (vertical
axis) versus protein concentration , horizontal axis).
Figures 3(a) h (e) are photographic representations of surviving colonies of
T. rubrum grown on agar plates after treatment with 100 MM HXLOOS for 72 h. Panels (a)
to (d) represent clinical isolates 14—01, 14—02, 14—03 and 13—04 respectively. Surviving
colonies are marked with a black rectangle. Panel (e) ents the growth of T. rubrum
that has not been d with HXLOOS.
Figure 4 is a representation of an amino acid alignment of HXLOOS, HXL035 and
HXL036 and a consensus sequence of these three sequences. Identical amino acids are
highlighted in black conserved amino acids are highlighted in grey.
DETAILED DESCRIPTION
hout this specification, unless the context requires otherwise, the word
“comprise” or variations such as “comprises” or “comprising”, will be tood to imply
the inclusion of a stated element or integer or method step or group of elements or integers
or method steps but not the exclusion of any element or integer or method step or group of
elements or rs or method steps.
As used in the subject specification, the singular forms “a”, “an” and “the” include
plural aspects unless the context clearly es otherwise. Thus, for example, reference to
“a defensin” includes a single defensin, as well as two or more defensins; reference to “an
WO 91790
—18-
agent” es single agent, as well as two or more agents; reference to “the disclosure”
includes a single and multiple aspects taught by the disclosure; and so forth. Aspects
taught and enabled herein are encompassed by the term “invention”. All such aspects are
enabled within the width of the present invention. Any ts and derivatives
contemplated herein are encompassed by “forms” of the invention.
Reference to a “defensin” means one or more of the following plant defensins
which retains antimicrobial activity.
(i) a defensin having the consensus amino acid sequence as set forth in SEQ ID
NO:24;
(ii) a defensin selected from the group consisting of HXLOOS (SEQ ID NOzl),
HXL035 (SEQ ID NO:2) and HXL036 (SEQ ID NO:3);
(iii) a defensin selected from the group consisting of HXLOOl (SEQ ID NO:4),
HXL002 (SEQ ID NO:5), HXP35 (SEQ ID NO:3), HXL003 (SEQ ID NO:6), HXL004
(SEQ ID NO:7), HXLOOS (SEQ ID NO:8), HXL009 (SEQ ID NO:9), HXLOl2 (SEQ ID
NO:lO), HXLOl3 (SEQ ID NO:ll), HXLOlS (SEQ ID NO:l2), HXL032 (SEQ ID
NOzl3), HXL033 (SEQ ID , HXL034 (SEQ ID , Nle (SEQ ID NO:l6),
NsD2 (SEQ ID NO:l7), NaDl (SEQ ID NO:18), NoDl73 (SEQ ID NO:l9), DmAMPl
(SEQ ID NO:20), HXP4 (SEQ ID , HXP34 (SEQ ID NO:22) and HXP35 (SEQ ID
NO:23).
(iv) a functional naturally occurring or synthetic derivative or variant of any one of
SEQ ID NO:1 through 47;
(v) a defensin having at least 80% similarity to any one of SEQ ID NO:1 through 47
after optimal alignment;
(vi) any one of SEQ ID NO:1 through 47 comprising a N—terminal alanine residue (i.e.
SEQ ID NO:25 through 47); and/or
(vii) a defensin having at least 80% similarity to any one of SEQ ID NO:1 through 3 or
after optimal ent.
In an embodiment the in is defined by SEQ ID NO: 1 though 3 or contains
an N—terminal alanine residue (SEQ ID NO: 25 through 27 respectively). For convenience
these defensins are encompassed within the consensus amino acid sequence set forth in
SEQ ID No: 24.
Reference hereinafter to a "defensin" or a in "defined herein", means a
defensin as listed in paragraphs (i) through (vii) above. The different ins
assed by (i) through (vii) represent ent forms of the subject invention.
When the defensin herein is used in combination with a microbicidic agent and that
icidic agent is a defensin, then the second defensin may be any in.
A ol is described herein which is used to facilitate management of microbial
infection or colonization at ular in vivo anatomical sites or regions in a human or
non—human animal subject. The protocol comprises the use of a plant defensin or a
functional natural or synthetic derivative or variant thereof to inhibit or otherwise control
the growth or colonization of a microorganism on or in in vivo tissue. The present protocol
excludes the ent of skin, hair and nails. However, reference to skin does not exclude
subcutaneous infection of skin or a surface wound. In an embodiment, the defensin has no
adverse activity or medically acceptable minimal activity against mammalian cells. In an
optional embodiment, the defensin is used in istic combination with another
antimicrobial agent. The latter agent includes a non—defensin peptide, a proteinase
inhibitor, another defensin and a proteinaceous or non—proteinaceous (chemical) agent with
antimicrobial properties including an antibiotic.
Examples of microbial infection include infection by fungi and bacteria. These
include aspergillosis, infection by Candida such as of mucosal membranes (e.g. ),
systemic candidiasis, cryptococcosis, subcutaneous infections such as mucorymycosis,
bacterial gastroenteritis, respiratory infection, wound infection and an infection leading to
a ly transmitted disease.
Enabled herein is a method for inhibiting infection by a microorganism on or in in
vivo tissue in a subject, the method comprising contacting the microorganism or tissue
comprising the microorganism with an ive amount of a plant defensin or a functional
natural or synthetic derivative or variant thereof. In an embodiment, the in vivo tissue is a
mucosal or epithelial al surface or tissue or a subcutaneous layer of skin. Hence,
taught herein is a method for inhibiting growth or colonization of a microorganism on or in
in vivo l or epithelial tissue or a subcutaneous layer, the method sing
ting the tissue or microorganism with an effective amount of a plant defensin or a
functional natural or synthetic variant or derivative thereof. Generally, the contact is for a
time and under conditions sufficient to inhibit growth of the microorganism. The
defensins can also be coated on the surface of medical devices such as catheters and
implants or condoms or other sheaths.
“Microbial inhibition” includes both iocidic and microbistatic activity, as
measured by reduction of microbial biomass (or loss of viability) compared to a control.
Microbial growth can be measured by many different methods known in the art depending
on the microorganism. For fungi, for example, a commonly used method of measuring
growth of a ntous fungus, entails germinating spores in a suitable growth medium,
incubating for a time sufficient to achieve able , and measuring increased
optical density in the culture after a specified incubation time. The optical density rises
with increased growth. Typically, microbial growth or colonization is necessary for
pathogenesis. Therefore, inhibition of pathogen growth provides a suitable indicator for
protection from microbial disease, i.e. the greater the inhibition, the more ive the
tion. Furthermore, the effectiveness of the microbicidal or microstatic activity can
be determined by microscopic examination or culture techniques from a sample or
amelioration of e symptoms (e.g. fever, s, tenderness etc.).
Reference to microorganism includes a fungus and a ium.
The treatment protocol includes prophylaxis (i.e. tion) of at risk subjects
from infection. A subject “at risk” may be a subject in a particular location or
demographic. Hence, “preventing infection” in the present context, means that the human
or animal host is treated with the defensin so as to avoid microbial infection or disease
symptoms associated therewith or exhibit reduced or minimized or less frequent microbial
infection or disease symptoms associate therewith, that are the natural outcome of the host—
rganism interactions when compared to the host not exposed to the defensin. That
is to say, microbial infection is prevented or reduced from causing disease and/or the
associated disease ms. Infection and/or symptoms are reduced by at least about
%, 20%, 30%, 40%, 50, 60%, 70% or 80% or greater as ed to a host not so
treated with the protocol taught herein. The percentage reduction can be determined by
any convenient means appropriate to the host and microorganism. The microorganism
may be naturally occurring in the t without being a "pathogen". However, situations
can arise where the microorganism multiplies to a level where it becomes pathogenic.
The action of the defensin is to inhibit microbial growth, replication, ion
and/or maintenance, amongst other inhibitory ties and/or induce amelioration of
ms of microbial infection when the level of rganism or its location in the
body (i.e. in the in viva , surface or membrane) results in a pathogenic outcome.
Enabled herein is a method for the treatment or prophylaxis of aspergillosis or a
related condition in a subject, the method comprising contacting an infected site on the
subject or administering to the subject a plant defensin or a functional natural or synthetic
derivative or variant thereof for a time and under conditions sufficient to ameliorate the
ms of aspergillosis.
In an embodiment, the microbial infection is infection by a species or strain of
Candida.
Enabled herein is a method for the treatment or prophylaxis of a infection of
a mucosal membrane in a t, the method comprising contacting an infected site on the
subject or administering to the subject a plant defensin or a functional l or synthetic
derivative or variant thereof for a time and under conditions sufficient to ameliorate the
symptoms of infection.
In an embodiment, the Candida infection leads to thrush.
In an embodiment, the microbial infection is ic candidiasis.
Hence, taught herein is a method for the treatment or prophylaxis of systemic
candidiasis in a t, the method comprising administering to the subject a plant
defensin or a functional natural or synthetic derivative or variant thereof for a time and
under conditions sufficient to rate the symptoms of infection.
In an embodiment, the microbial infection is cryptococcosis.
Hence, taught herein is a method for the ent or prophylaxis of cryptococcosis
in a subject comprising contacting an infected site on the subject or administering to the
subject a plant in or a functional l or synthetic derivative or variant thereof for
a time and under conditions sufficient to ameliorate the symptoms of infection.
In an embodiment, the microbial infection is mucormycosis or a related condition.
According, enabled herein is a method for the treatment or prophylaxis of mucyrmycosis
in a subject comprising contacting an infected site on the subject or administering to the
t a plant defensin or a functional natural or synthetic derivative or variant thereof for
a time and under conditions sufficient to ameliorate the symptoms of infection.
In an embodiment, the microbial infection is a subcutaneous infection. Hence,
taught herein is a method for the treatment or prophylaxis of infection of a subcutaneous
skin layer in a subject, the method comprising contacting an infected site on the subject or
administering to the subject a plant in or a functional natural or synthetic derivative
or variant thereof for a time and under conditions sufficient to ameliorate the ms of
infection.
In an embodiment, the microbial infection is lasmosis. Hence, taught herein
is a method for the ent or prophylaxis of histoplasmosis in a subject comprising
contacting an ed site on the subject or administering to the subject a plant defensin or
a functional natural or synthetic derivative or variant thereof for a time and under
conditions sufficient to ameliorate the symptoms of infection.
In an embodiment, the microbial infection leads to gastroenteritis.
Hence, the present specification is instructional for a method for the treatment or
prophylaxis of microbial gastroenterisits in a subject comprising administering to the
subject a plant defensin or a functional natural or synthetic tive or variant thereof for
a time and under conditions sufficient to ameliorate the symptoms of infection.
In an ment, the ial infection is a respiratory infection.
d herein is a method for the treatment or prophylaxis of respiratory infection
in a subject, the method comprising administering to the subject a plant defensin or a
functional natural or synthetic derivative or t thereof for a time and under conditions
sufficient to ameliorate the symptoms of infection.
In an embodiment, the microbial infection is a wound infection.
The subject specification teaches a method for the treatment or prophylaxis of a
wound ion in or on a subject, the method comprising contacting the wound on the
subject or administering to the subject a plant defensin or a functional natural or tic
derivative or variant thereof for a time and under ions sufficient to ameliorate the
symptoms of infection.
In an embodiment, the microbial infection leads to a sexually transmitted disease.
Hence, d herein is a method for the treatment or prophylaxis of ly
transmitted disease in a subject, the method comprising contacting an infected site on the
subject or administering to the subject a plant defensin or a functional l or synthetic
derivative or variant thereof for a time and under conditions sufficient to ameliorate the
symptoms of infection.
In an embodiment, the in or its functional natural or synthetic derivative or
variant is coated on to the surface of a medical device or condom. Examples of medical
devices e catheters and implants. Any of the defensins defined herein may be used
in these methods such as but not limited to a in defined by the consensus amino acid
sequence SEQ ID NO:24 or a onal natural or synthetic derivative or variant thereof
which includes a defensin having at least 80% similarity to SEQ ID NO: 24 after optimal
alignment or wherein SEQ ID NO:24 has an optional inal alanine residue.
Examples include SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 and variants thereof
with an N—terminal alanine residue (SEQ ID NO:25 though 27, respectively)..
By “contacting” includes exposure of the rganism or tissue, surface or
membrane or site comprising the microorganism to the defensin following administration
or application to the human or animal subject. It also includes systemic, local, topical or
parenteral administration to the subject or an infected site. Contact may be with a purified
plant defensin or formulation comprising same, or a plant extract which comprises the
defensin naturally or which has been engineered to produce the defensin. A formulation
includes herbal formulations and ceutical formulations. Reference to “contacting”
includes the step of administering to a subject or an infected site on a t.
Enabled herein is a formulation comprising a plant defensin or a functional natural
or synthetic derivative or variant thereof for use in inhibiting infection by a microrganism
on or in in vivo tissue in a human or animal subject.
Further enabled herein a use of a formulation comprising a plant defensin or a
functional natural or synthetic derivative or variant thereof in the manufacture of a
medicament for inhibiting infection by a rganism on or in in vivo tissue in a human
or animal subject.
Also d is a formulation comprising a plant defensin or a functional natural or
tic derivative or variant f when used to inhibit infection by a microorganism
on or in in vivo tissue in a human or animal subject.
In an embodiment, taught herein is a therapeutic kit comprising a compartment or
in tmental form wherein a compartment comprises a plant defensin or a functional
natural or synthetic derivative or variant thereof. Second or further compartments may
comprise other agents or ents including other antimicrobial agents such as an
antibiotic or other microbicidal or microbistatic agent. The contents of each compartment
may be d prior to use or used sequentially in any order. Other antimicrobial agents
e non—defensin peptides, a proteinase inhibitor, another defensin or a proteinaceous
or chemical (non—proteinaceous) antimicrobial agent including an antibiotic.
Reference to a “plant defensin” means those defined herein with reference to
Tables 1 and 2. As defined herein, a defensin includes a defensin having at least about
80% similarity to any one of SEQ ID NO:1 h 47. The 80% similarity is determined
after optimal alignment and, where necessary, after appropriate spaces are used to optimize
the alignment. By “at least 80%” or “at least about 80%” includes 80, 81, 82, 83, 84, 85,
86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 and 100%. In an embodiment, the
defensin is defined by the consensus amino acid sequence SEQ ID NO:24 or a functional
natural or synthetic derivative or variant thereof which includes a defensin having at least
80% similarity to SEQ ID NO: 25 after optimal alignment wherein SEQ ID NO:24 has an
optional inal alanine residue. Examples include SEQ ID NO;l, SEQ ID NO:2 and
SEQ ID NO:3 and their N—terminal alanine variants, SEQ ID NO: 25 through 27,
respectively). Some defensins use herein may be referred to as “naturally ing’,
“modified”, “variant:9 6‘mutated”, “synthetic derivative or variant” a ric” defensins.
All such defensins retain crobial activity..
Hence, taught herein is a method for inhibiting infection by a microorganism on or
in in vivo tissue in a subject, the method comprising contacting the microorganism or tissue
sing the microorganism or administering to the subject an effective amount of plant
—26-
defensin ed from SEQ ID NO:1 h 47 or a functional natural or synthetic
derivative or variant thereof or a defensin having at least 80% similarity to any one of SEQ
ID NO:1 through 47 after optimal alignment for a time and under conditions sufficient to
ameliorate symptoms of the infection. The defensin may have an N—terminal alanine
e such as SEQ ID NO:25 through 47.
The term arity" as used herein includes exact identity between compared
sequences at the amino acid level. Where there is non—identity at the amino acid level,
"similarity" includes amino acids that are nevertheless related to each other at the
structural, functional, biochemical and/or conformational levels. In an embodiment, amino
acid sequence isons are made at the level of identity rather than similarity.
Terms used to describe sequence relationships between two or more polypeptides
include "reference sequence", "comparison window", "sequence similarity", "sequence
identity", ntage sequence similarity", "percentage sequence identity", "substantially
similar" and "substantial identity". A "reference sequence" is at least 12 but frequently 15
to 18 and often at least 25 or above, such as 30 amino acid residues in length. Because two
polypeptides may each comprise (l) a sequence (i.e. only a portion of the complete amino
acid sequence) that is similar between the two polypeptides, and (2) a sequence that is
divergent between the two polypeptides, sequence comparisons between two (or more)
polypeptides are typically performed by comparing ces of the two polypeptides over
a "comparison window" to identify and compare local s of sequence similarity. A
"comparison window" refers to a conceptual segment of typically 12 contiguous es
that is compared to a reference sequence. The comparison window may comprise additions
or deletions (i.e. gaps) of about 20% or less as compared to the nce sequence (which
does not comprise additions or deletions) for optimal alignment of the two ces.
Optimal alignment of sequences for aligning a comparison window may be conducted by
computerized implementations of algorithms (GAP, BESTFIT, FASTA, Clustal W2 and
TFASTA in the Wisconsin Genetics re Package Release 7.0, Genetics Computer
Group, 575 Science Drive Madison, WI, USA) or by inspection and the best alignment (i.e.
ing in the highest tage homology over the comparison window) generated by
any of the various methods selected. Reference also may be made to the BLAST family of
programs as for example disclosed by Altschul et al. (1997) Nucl. Acids. Res. 25(17).'3389—
3402. A detailed discussion of sequence is can be found in Unit 19.3 of l et
al. (1994-1998) In: Current Protocols in Molecular Biology, John Wiley & Sons Inc.
Other alignment software includes BWA (Li and Durbin (2010) Bioinformatics 26: 589-
595) and Bowtie (Langmead et al (2009) Genome Biol 10:R25 and BLAT (Kent (2002)
Genome Res 122656—664).
The terms "sequence similarity" and nce identity" as used herein refer to the
extent that sequences are identical or functionally or structurally similar on an amino acid—
no acid basis over a window of comparison. Thus, a "percentage of sequence
identity", for example, is calculated by comparing two optimally d sequences over
the window of comparison, determining the number of positions at which the cal
amino acid residue (e.g. Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His,
Asp, Glu, Asn, Gln, Cys and Met) occurs in both ces to yield the number of
matched positions, dividing the number of matched positions by the total number of
positions in the window of comparison (i.e., the window size), and multiplying the result
by 100 to yield the percentage of sequence identity. For the purposes of the present
invention, "sequence ty" will be understood to mean the "match percentage"
calculated by any suitable method or er algorithm using standard defaults as used in
the reference manual accompanying the software. Similar comments apply in relation to
sequence similarity.
Some defensins used herein may be referred to herein as a “naturally occurring”
defensin, a “modified” defensin, a “variant” defensin, a “mutated” defensin or a “chimeric”
defensin, depending on its source.
In an embodiment, the defensin is a Class II Solanaceons defensin. In an
embodiment, the defensin is modified at the loop region between the first B—strand (B—
strand 1) and the oc—helix at the N—terminal end portion of the defensin. In an embodiment,
the loop region comprises the 6 amino acids N—terminal of the second invariant cysteine
—28-
residue or its equivalent. This region is defined as “LooplB”. A Class II Solanaceous
defensin is distinguished from other defensins by a relatively conserved inal end
n of the mature domain.
Included herein is the use of an artificially created defensin comprising a modified
Class II ceous defensin backbone n the loop region between B—strand 1 and
the oc—helix on the N—terminal end n is modified by a single or multiple amino acid
substitution, addition and/or deletion to te a variant defensin which has anti—
pathogen activity. In an embodiment, the loop region is LooplB defined by the 6 amino
acid residues N—terminal to the second invariant cysteine residue. Its equivalent region in
any defensin is plated herein. In an embodiment, the artificially created defensin
comprises a modified Class II defensin.
Examples of suitable defensins are defined by amino acid ce (Table 1) and
further characterized in Table 1. These comprise synthetic defensin variants such as HXP4
(SEQ ID NO:21), HXP34 (SEQ ID N022) and HXP35 (SEQ ID NO:23) or the same
defensins with an N—terminal alanine residue (SEQ ID NO:45, 46 and, 47, respectively).
Taught herein is a method for inhibiting infection by a microorganism, on or in in
viva tissue in or on a subject, the method comprising contacting the microorganism or
tissue comprising the microorganism or administering to the subject with an effective
amount of a plant in selected from the group consisting of SEQ ID NO:1 h 47
or functional derivative or variant thereof. Generally, the defensin is applied for a time and
under conditions sufficient to ameliorate the symptoms of the infection.
The defensin may be provided at a concentration of between 0.1% and 100% w/v,
at a frequency of once a day, twice a day, once every two days, once a week, once every
two weeks or once a month, for a period of one week, two weeks, three weeks, one month,
two months, three months or up to 12 months.
In an optional embodiment, the defensin or its tive or variant is used in
combination with another antimicrobial agent. It is proposed that the in and the
antimicrobial agent act in synergy. Examples of other agents include a non—defensin
antimicrobial peptide, a proteinase tor another defensin or a proteinaceous or non—
proteinaceous chemical microbicide including an antibiotic.
Reference to synergy means that the inhibitory effect of a given defensin or other
agent alone is greater when both are used er compared to either used alone. Greco er
al. (1995) Pharmacol Rev. 47:331—385 define a category of synergy on the basis that the
use of two agents in combination has greater ty relative to the additive effects when
each is assayed alone. Hence, the definition adopted herein includes all such situations
provided that the combined effect of the two agents acting together is greater than the sum
of the individual agents acting alone. Furthermore, a combination of agents is deemed
istic, as the term is intended herein, if there exists a set of ions, including but
not limited to concentrations, where the combined effect of the agents acting together is
greater than the sum of the individual components acting alone. Richer (1987) Pestic Sci
19:309—315 describes a mathematical approach to establish proof of y. This
approach uses Limpel’s formula for comparing an observed level of inhibition (Io) in the
combined ce of two inhibitor agents, X and Y, with an expected additive effect (Ee)
resulting from each X or Y acting separately at the same respective concentrations as used
to measure their combined effect. Additive percent inhibition, Be, is calculated as X + Y —
XY/100 where X and Y are expressed as percent inhibition. Synergism exits where Io >
Synergy may be sed as a synergy scale. In an embodiment, a value of up to
14 represents no significant synergy such as 0, l, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14;
a value of from 15 up to 29 represents low synergy such as 15, l6, 17, 18, 19, 20, 21, 22,
23, 24, 25, 26, 27, 28 or 29; a value of from 30 to 60 represents medium synergy such as
, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53,
54, 55, 56, 57, 58, 59 or 60; a value greater than 60 represents a high degree of synergy.
By er than 60” includes from 61 to 100 including 61, 70, 80, 90 and 100 and any
value in between.
The present method is useful in the treatment or laxis of a t having an
infection on or in an in vivo tissue. The defensins defined by SEQ ID NO:1 through 47 are
defined in Tables 1 and 2. The present invention encompasses the treatment of any
internal e tissue or membrane which is not external skin, hair or nails. Reference to
"external skin" does not exclude subcutaneous layers of external skin or a surface wound.
The term ct” includes a human of any age or an animal such as a farm animal (e.g.
sheep, pig, horse, cow, donkey, camel, llama, alpaca) or poultry bird (e.g. chicken, duck,
turkey, pheasant, peacock), companion animal (e.g. dog or cat), laboratory test animal (e.g.
mouse, rat, rabbit, guinea pig or hamster) or captive wild animal (e.g. wild goat).
The microorganism may be a fungus or a bacterium. Reference to a s”
includes dermatophytes, yeasts and non—dermatophytic molds (non—dermatophytes).
Dermatophytes include Trichophyton species including Trichophyton rubrum,
Trichophyton igitale, Trichophyton violaceum, Trichophyton tonsurans,
Trichophyton ense and Trichophyton mentagrophytes, Microsporum fulvum,
Epidermophyton floccosum and Microsporum gypseum. Yeasts encompasses Candida
species including Candida albicans, Candida glabrata, Candida parasilosis, Candida
tropicalis and Candida . Cryptococcus species including coccus neoformans
and Cryptococcus gattii, and Malassezia species including Malassezia a, Malassezia
furfur, Malassezia dermatis and Malassezia restricta and Penicillium marnefi‘ei. Non—
dermatophytic molds include species of Aspergillus including Aspergillus fumigatus,
Aspergillus flavus, Aspergillus terreus and Aspergillus niger, Rhizopus s including
Rhizopus oryzae, Neoscytalidium, Scopulariopsis, Acremonium, Fusarium species
including Fusarium solani, Fusarium and oxysporum,, Scytalidium and. Oomycetes
include m insidiosum. Reference to a bacterium es Staphylococcus spp,
ococcus ssp, ella spp, Proteus spp, E. coli spp, Bacillus spp, Mycobaterium
spp, Mycoplasma spp, Bacteroides spp, Fusobacterium spp.
The component or extract is administered with a pharmaceutical carrier, which is
non toxic to cells and the individual.
The carrier may take a wide variety of forms depending on the form of preparation
desired for administration, e.g., oral or parenteral (including intravenous) or systemic. In
preparing the compositions for oral dosage form, any of the usual pharmaceutical media
may be employed, such as, for example, water, glycols, oils, alcohols, flavouring agents,
preservatives, colouring agents and the like in the case of oral liquid preparations, such as,
for example, sions, elixirs and ons; or carriers such as starches, sugars,
microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating
agents and the like in the case of oral solid preparations such as, for example, powders,
capsules and tablets, with the solid oral preparations being preferred over the liquid
preparations. Because of their ease of administration, tablets and capsules represent the
most advantageous oral dosage unit form in which case solid pharmaceutical carriers are
obviously ed. If desired, s may be coated by rd aqueous or nonaqueous
techniques.
Pharmaceutical compositions of the present invention used for therapy suitable for
oral stration may be presented as discrete units such as capsules, cachets or tablets
each containing a predetermined amount of the active ingredient, as a powder or es
or as a solution or a suspension in an aqueous liquid, a non—aqueous liquid, an oil—in—water
on or a water—in—oil liquid emulsion. Such compositions may be prepared by any of
the methods of pharmacy but all methods e the step of bringing into association the
active ingredient with the carrier which constitutes one or more necessary ingredients. In
general, the compositions are prepared by uniformly and intimately admixing the active
ingredient with liquid carriers or finely divided solid carriers or both, and then, if
necessary, shaping the product into the d presentation. For e, a tablet may be
prepared by ssion or molding, optionally with one or more ory ingredients.
Compressed tablets may be ed by compressing in a suitable machine, the active
ingredient in a free—flowing form such as powder or granules, optionally mixed with a
binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be
made by molding in a suitable machine, a mixture of the powdered compound moistened
with an inert liquid diluent.
2015/050294
The components and/or ts identified of the present invention may be
administered orally, parenterally or systemically (including subcutaneous injections,
enous, intramuscular, intraperitoneal intrastemal injection, intranasal or infusion
techniques), by inhalation spray, or rectally, in dosage unit formulations containing
conventional non—toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
When administered by nasal aerosol or tion, these compositions are prepared
according to techniques well—known in the art of pharmaceutical formulation and may be
prepared as solutions in , employing benzyl alcohol or other le vatives,
absorption promoters to enhance bioavailability, arbons, and/or other solubilizing or
dispersing agents known in the art.
The defensins of the invention may also be stered in enous (both bolus
and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or
intramuscular form, all using forms well known to those of ordinary skill in the
pharmaceutical arts. When administered by injection, the injectable solutions or
suspensions may be formulated according to known art, using suitable non—toxic,
parenterally—acceptable diluents or solvents, such as mannitol, l,3—butanediol, water,
Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and
suspending , such as sterile, bland, fixed oils, including synthetic mono— or
diglycerides, and fatty acids, including oleic acid.
When rectally administered in the form of suppositories, these itions may be
prepared by mixing the drug with a suitable non—irritating excipient, such as cocoa butter,
synthetic glyceride esters or polyethylene glycols, which are solid at ordinary
temperatures, but liquidify and/or dissolve in the rectal cavity to release the drug.
The ive dosage of the defensins employed in therapy may vary depending on
the ular compound employed, the mode of administration, the condition being treated
and the severity of the condition being treated. Thus, the dosage regimen utilizing the
compounds of the present invention is selected in accordance with a variety of factors
including type, species, age, weight, sex and medical condition of the patient; the severity
of the condition to be treated; the route of administration; the renal and hepatic function of
the patient; and the particular compound thereof employed. A physician, clinician or
veterinarian of ordinary skill can readily determine and prescribe the effective amount of
the drug required to prevent, counter or arrest the progress of the condition. Optimal
precision in achieving tration of drug Within the range that yields efficacy Without
toxicity requires a regimen based on the kinetics of the drug's availability to target sites.
This involves a consideration of the distribution, equilibrium, and elimination of a drug.
The defensin may be administered ly to the ed site or provided
systemically or by other convenient means generally for a time and under conditions
sufficient to ameliorate the symptoms of infection.
Another aspect provides a protocol or method for treating or preventing an animal
including a mammalian such as a human subject having in viva tissue ed with a
microorganism, the protocol or method comprising stering to the subject or site of
infection an antimicrobial effective amount of a composition comprising the plant defensin
for a time and under conditions sufficient to treat the infection.
The present defensin may be manufactured based on its amino acid sequence using
standard stepwise addition of one or more amino acid residues using, for example, a
peptide or protein synthesizer. atively, the defensin is made by recombinant means.
A recombinant defensin may include an additional alanine e at its N—terminus.
Hence, ins contemplated herein may contain the N—terminus alanine residue.
In addition, the defensin may be subject to chemical modification to render the
defensin a chemical analog. Such defensin , may exhibit greater ity or longer
half life at the point of t with the tissue.
Analogs contemplated herein include but are not limited to modification to side
chains, incorporating of unnatural amino acids and/or their derivatives during peptide,
ptide or protein sis and the use of crosslinkers and other methods which
impose conformational constraints on the defensin molecule. This term also does not
exclude modifications of the defensin, for example, ylations, acetylations,
phosphorylations and the like. Included within the definition are, for example, defensins
containing one or more analogs of an amino acid (including, for e, unnatural amino
acids) or defensins with substituted linkages. Such analogs may have enhanced stability
and/or penetrability.
Examples of side chain modifications contemplated by the present invention
e modifications of amino groups such as by reductive alkylation by reaction with an
aldehyde followed by reduction with NaBH4; amidination with methylacetimidate;
ion with acetic anhydride; carbamoylation of amino groups with cyanate;
trinitrobenzylation of amino groups with 2, 4, 6—trinitrobenzene sulphonic acid (TNBS);
acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and
xylation of lysine with pyridoxal—5—phosphate followed by reduction with NaBH4.
The guanidine group of arginine residues may be modified by the formation of
heterocyclic condensation ts with ts such as 2,3—butanedione, phenylglyoxal
and glyoxal.
The carboxyl group may be modified by carbodiimide activation via O—acylisourea
ion followed by subsequent derivitisation, for example, to a corresponding amide.
Sulphydryl groups may be modified by methods such as carboxymethylation with
etic acid or etamide; performic acid oxidation to cysteic acid; formation of a
mixed disulphides with other thiol compounds; reaction with maleimide, maleic ide
or other substituted ide; formation of mercurial derivatives using 4—
chloromercuribenzoate, 4—chloromercuriphenylsulphonic acid, phenylmercury chloride, 2—
chloromercuri—4—nitrophenol and other mercurials; carbamoylation with cyanate at alkaline
Tryptophan residues may be modified by, for example, oxidation with N—
bromosuccinimide or alkylation of the indole ring with 2—hydroxy—5—nitrobenzyl bromide
or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with
itromethane to form a 3—nitrotyrosine derivative.
Modification of the imidazole ring of a histidine residue may be accomplished by
alkylation with iodoacetic acid derivatives or N—carbethoxylation with
diethylpyrocarbonate.
es of incorporating ral amino acids and derivatives during peptide
synthesis include, but are not limited to, use of norleucine, 4—amino c acid, 4—amino—
3—hydroxy—5—phenylpentanoic acid, 6—aminohexanoic acid, t—butylglycine, norvaline,
phenylglycine, ornithine, sarcosine, 4—amino—3—hydroxy—6—methylheptanoic acid, 2—thienyl
alanine and/or D—isomers of amino acids. A tional inkers such as the
bifunctional imido esters having (CH2)n spacer groups with n = l to n = 6, glutaraldehyde,
N—hydroxysuccinimide esters and hetero—bifunctional reagents which usually contain an
amino—reactive moiety such as N—hydroxysuccinimide and another group specific—reactive
moiety such as maleimido or dithio moiety (SH) or carbodiimide . In addition,
peptides can be conformationally constrained by, for example, incorporation of COL and N
0t—methylamino acids, introduction of double bonds between COL and CB atoms of amino
acids and the formation of cyclic peptides or analogs by introducing covalent bonds such
as forming an amide bond between the N and C termini, between two side chains or
between a side chain and the N or C terminus.
Mimetics are another useful group of defensin analog. The term is intended to refer
to a substance which has some chemical similarity to the defensin and mimics its anifungal
activity. A peptide mimetic may be a peptide—containing molecule that mimics elements of
protein secondary structure (Johnson et al., Peptide Turn Mimetics in Biotechnology and
Pharmacy, Pezzuto et al., Eds., Chapman and Hall, New York, 1993). The underlying
rationale behind the use of peptide cs is that the e backbone of ns exists
chiefly to orient amino acid side chains in such a way as to facilitate activity actions.
As used herein, “comprising” is synonymous with “including,:9 encontaining,” or
cterized by,” and is inclusive or nded and does not exclude additional,
unrecited ts or method steps. As used herein, “consisting of” excludes any element,
step, or ingredient not specified in the claim element. As used herein, “consisting
essentially of” does not exclude materials or steps that do not materially affect the basic
and novel characteristics of the claim. Any recitation herein of the term ising”,
particularly in a description of components of a composition or in a description of elements
of a device, is understood to encompass those compositions and s consisting
essentially of and consisting of the recited ents or elements. The present disclosure
illustratively described herein suitably may be practiced in the absence of any element or
elements, limitation or limitations which is not specifically disclosed .
When a Markush group or other grouping is used herein, all individual members of
the group and all combinations and sub—combinations possible of the group are intended to
be individually included in the disclosure.
When a range is recited herein, it is intended that all sub—ranges Within the stated
range, and all integer values Within the stated range, are intended, as if each nge and
integer value was recited.
EXAMPLES
Aspects disclosed and enabled herein are now described in the following non—
limiting Example.
Methods
Purification of ins from Pichia Pastoris
A single pPINK—defensin P. pastoris PichiaPink (Trademark) strain 1 colony is
used to inoculate 25 mL of BMG medium (described in the Invitrogen Pichia sion
Manual) in a 250 mL flask and that is incubated over for 2—3 days in a 30°C shaking
incubator (140 rpm). The culture is used to inoculate 200 mL of BMG in a 1 L baffled
flask which is placed in a 30°C shaking incubator (140 rpm) overnight. The cells are
harvested by centrifugation (1,500 x g, 10 min, 4°C) and resuspended into 1 L of BMM
medium in a 5 L baffled flask and incubated in a 28°C shaking incubator for 3 days (2 days
for NaDl). The cultures are induced at t=24 and 48h. The expression medium is separated
from cells by centrifugation (6000 rpm, 20 min, 4 °C). The medium is adjusted to pH 3.0
before it is applied to an SP Sepharose column (1 cm x 1 cm, Amersham Biosciences) pre—
equilibrated with 100mM potassium ate buffer, pH 6.0. The column is then washed
with 100 mL of 100mM potassium phosphate buffer, pH 6.0 (wash x 2 for HXL004).
Bound protein is eluted in 10x10 mL of 100mM potassium ate buffer containing
500 mM NaCl. A dot blot is performed to identify factions with the t concentration
of eluted protein and those fractions are concentrated down to 1 mL using a centrifugal
column and washed 5x using sterile milli Q ultrapure water. The n concentration of
Pichia—expressed defensin is determined using the bicinchoninic acid (BCA) protein assay
(Pierce Chemical Co.) with bovine serum albumin (BSA) as the protein standard.
The defensins contemplated for use herein are listed in Tables 1 and 2 and include
defensins having at least 80% similarity to any one of the listed ins after l
alignment.
—38-
s 1(a) through (e) provide an alignment showing the similarity of amino acid
sequences between a number of defensins. Figure 4 provides an alignment of amino acids
sequences for HXLOO8 (SEQ ID No: 1), HXL035 (SEQ ID No: 2), and HXL036 (SEQ ID
No: 3). This alignment issued to generate a consensus amino acid sequence set for the in
SEQ ID NO: 24. Any of these sequences may contain an optional N-terminal alanine
residue.
EXAMPLE 1
Inhibition ofthe growth of Trichophyton rubrum and Microsporumfulvum in the
presence ofa plant defensin
Plant ins include a ceous Class II defensin (NaDl), a modified
LooplB variant (HXP4) and Class I ins (HXLOOI, HXLOOZ, HXL004. HXLOOS,
HXLOOS, HXL009, HXL012. HXL013, HXL015).
The inhibitory effects of the plant defensins on the growth of Trichophyton rubrum.
T. interdigitale, Micrmporum flrlvum and C. albicans (all obtained from the National
Mycology Reference Centre, South Australia Pathology at the Women’s and Children's
Hospital, Adelaide, lia ) are measured essentially as described by Broekaert et a].
(1990) FEMS Microbiol Lett 69:55-59.
Spores of T. rubrum, T. interdigitale and M fitlvum are ed from sporulating
fungus growing on 1/2 strength Sabouraud se agar. Spores were removed from the
plates by the addition of 1/2 strength potato dextrose broth (PDB). C. albicans cells are
grown in Yeast Peptone Broth (YPD) for 16 h. Spore and cell concentrations are measured
using a tometer.
Antifungal assays are ted in 96 well microtitre plates essentially as herein
described. Wells are loaded with 20 u L of filter sterilized (0.22 u m syringe filter.
Millipore) defensin (10x stock for each final concentration) or water and 80 u L of 5 X 104
spores/mL (T. , T, interdigitale, M. fulvum) or 5,000 cells/mL (C. albicans) in 1/2
strength PDB. The plates are incubated at 300C. Fungal growth is assayed by measuring
optical y at 595nm (A595) using a microtitre plate reader (SpectraMaX Pro MZ;
RECTIFIED SHEET (RULE 91) ISA/AU
Molecular Devices. Growth is allowed to proceed until the optical density (OD) of the
fungus in the absence of any test defensin reached an OD of 0.2. Each test is performed in
duplicate.
After incubation for 72 h, the media from wells containing clinical isolates of T.
rubrum incubated with 100 g/mL HXLOOS was plated onto fresh Sabouraud dextrose agar.
Plates were incubated at 30°C for 5 days to allow colonies to develop before being
photographed.
The results of the inhibition assays are shown in Table 3. HXLOOS, HXLOOS and
HXL035 are the most effective plant defensins across the range of fungal pathogens.
HXLOOl and HXL009 did not y any ty at the concentrations tested. HXL002
and NaD2 are very poor inhibitors of M. fulvum and C. albicans. HXL004, HXLOl2,
HXLOl3 and HXLOlS display intermediate activity across the range of pathogens.
The results of inhibition of clinical isolates of T. rubrum by HXLOOS (solid line)
and NaDl (dashed line) are shown in Figures 2(a) to 2(d). Both peptides inhibited fungal
growth at low concentrations with ICSOs of below 20 ug/mL against four clinical es.
However, in all cases HXLOOS ted growth at a lower concentration than NaDl.
The results of cell survival assays for clinical isolates of T. rubrum are shown in
Figures 3(a) to 3(e). Plates that had been ated with cells that had not been incubated
with a plant defensin were almost completely covered in . In st, plates that
were inoculated with cells had been incubated in the presence of HXLOOS for 72 h only
had l—3 colonies indicating that almost all the cells were dead.
TABLE 3
1C50 “.350 {C(53) 153-50
Baffin sin against '3“. againsi M. against 5’ against (.7,
min‘zmz uf’zti‘mm inmrdigimie albicazrs
( 3,3, gh'rfl...) ggigin'11_3)( 331 gin'11_,) (53 ghnL)
E-EXMK) 1 >MM :> 100 35
HXLGGZ 53’) 35
HX [.003 > 1 {)3} >103)
HXUKM i2, 1‘) ‘26:)
Lu 1!! 2?;
HXLOGS Lu L33 n
HXLGG?) 3 333.3
HXL‘Z} 1 2 42
HKB}? 3 :23;
HXLO 1 5 3mm(EN U4! ‘Ji
HX3,935 1%.} i. 8
NaDZ 4'3
N233} as E0 29
EXAMPLE 2
Inhibition ofthe growth al pathogens in the presence ofa plant defensin
Plant defensins include a ceons Class II defensin (NaDl) and Class I
defensins (HXL001, HXL002, HXL003, HXL004, HXL005, HXL008, HXL009, HXL012,
, HXL015, HXL035, NaD2).
The tory effects of the plant defensins on the growth of Candida albicans,
Aspergillus fumigatus (obtained from the National Mycology Reference Centre, South
Australia ogy at the Women’s and en's Hospital, Adelaide, lia ), C.
glabrata, C. tropicalis, A. flavns, A. niger, A. fumigatns, Cryptococcus neoformans and C.
gattii (obtained from Dee Carter, University of Sydney, New South Wales, Australia) are
measured essentially as described by Broekaert et al. (1990) FEMS Microbiol Lett 69:55—
Spores of A. flavns, A. niger and A. fumigatns are isolated from sporulating fungus
g on 1/2 strength Sabouraud dextrose agar. Spores were removed from the plates
by the addition of 1/2 th potato dextrose broth (PDB). C. albicans, C. glabrata, C.
alis, C. neoformans and C. gattii cells are grown in Yeast Peptone Broth (YPD) for
16 h. Spore and cell concentrations are measured using a hemocytometer.
Antifungal assays are conducted in 96 well microtitre plates essentially as herein
described. Wells are loaded with 20 u L of filter sterilized (0.22 u m syringe filter,
Millipore) defensin (10X stock for each final concentration) or water and 80 u L of 5 X 104
spores/mL (A. flavns, A. niger, A. fumigatns), 5,000 cells/mL (C. albicans, C. glabrata, C.
tropicalis) or 1 X 106 cells/mL (C. neoformans, C. gattii) in 1/2 strength PDB. The plates
are incubated at 30°C. Fungal growth is assayed by measuring optical density at 595nm
(A595) using a microtitre plate reader (SpectraMaX Pro M2; Molecular Devices. Growth is
allowed to proceed until the optical density (OD) of the fungus in the absence of any test
defensin reached an OD of 0.2. Each test is performed in duplicate.
The results from the antifungal assay are presented in Table 4.
TABLE 4
1650 1*”«5r:- {£50 ,
“~50., laww {Cs-:1 16:50
Defens 11 against {7. 231111351: C. against C. against: A. against: A. ages 11131 A. against C. againsi (.7.
afbimfis 31%?)mm impica 3:13: flaws n igu r fidfi’iigai 11.3; neqz‘mmmw gt; 1 2’5 i
(1: gx'mL) 1’1: gz’mL) ( 11 315/111le 1’_p E/mL’i (11 gme) {11 131mm
HXIJXN .351 6 > C-(C! >1 {)0 > 1(be- 1 1:) 41>
H); {.002 GE? 2!}
EB \Ia “106 >101 :> i {)0
SL > 01".: 4-3 21‘)
HXIJikfi-S
HKLOGe‘é
H}; {.009 (I:
l—DLLU 1 2 L‘x’!
HXLG 1 3. 12 T» 1 {JC- 1.5
113411015
HXL035 10
NeaDZ r} .-‘
2;3 4>Lh 20
N3D 1 14 Lu
2015/050294
EXAMPLE 3
Inhibition ofthe growth ofEscherichia coli and Bacillus subtilis in the presence ofplant
defensins
A single E. coli or B. subtilis colony was used to inoculate 5 ml of Luria—Bertani
media and grown overnight at 37°C. The following day, the optical y of the culture was
measured and the bacteria diluted to an l y at 600 nm (OD600) of 0.01 in Mueller—
Hinton Broth. Diluted E. coli or B. subtilis were added to 96—well plates with defensins at
concentrations of 20 uM, 10 uM, 5 uM, 2.5 uM, l.25 uM, 0.625 uM or 0.3125 uM. Plates
were read at OD595 to obtain time zero data points. Plates were incubated at 37°C for 18 hours
before reading again at OD595 to assess the amount of bacterial growth.
The results of inhibition of E. coli and B. subtilis are shown in Table 5. The plant
in HXL004 inhibited the growth of both E. coli and B. subtilis with IC50s of 2.5 and 2.6
uM tively. This activity is similar to the LL37 control for E. coli. HXL012 and
HXL013 inhibited growth of B. subtilis with IC50s of 20 and 10 uM respectively. The
defensins HXLOOl, HXL002, HXL003, HXL005, HXL008 and NaDl did not inhibit the
growth of E. coli or B. subtilis at the concentrations tested.
Table 5
IC50 against IC50 against B.
E. coli ( M) subtilis( M)
HXLOOI >20 >20
HXL002 >20 >20
HXL003 >20 >20
HXL004 2.5 2.6
HXL005 >20 >20
HXL008 >20
HXL009 >20 >20
HXL012 >20 20
HXL013 >20 10
NaDl >20
LL37 2.5
Those skilled in the art Will iate that the disclosure described herein is
susceptible to variations and modifications other than those ically described. It is to be
understood that the disclosure contemplates all such variations and modifications. The
disclosure also enables all of the steps, features, compositions and compounds ed to or
indicated in this specification, individually or collectively, and any and all combinations of
any two or more of the steps or features or compositions or compounds.
BIBLIOGRAPHY
ul et al. (1997) Nucl. Acids. Res. 25(17).'3389—3402
Ausubel et al. (1994—1998) In: Current Protocols in Molecular Biology, John Wiley &
Sons Inc
Bloch and Richardson (1991) FEBS Lett :101—104
Broekaert et al. (1990) FEMS Microbiol Lett 69:55—59
Cabral et al., (2003) Protein Expres Purif3](]):115—122
Colilla et al. (1990) FEBS Lett 270(1-2):191—194
Fisher et al. (1981) The American Journal ofMedicine 71 (4):571—7
Gomes et al. (2011) Clinical Microbiology Reviews 24(2):411—45
Greco et al. (1995) col Rew —385
Janssen et al. (2003) Biochemistry 42(27):8214—8222
Johnson et al., Peptide Turn Mimetics in Biotechnology and Pharmacy,Pezzuto et al., Eds.,
Chapman and Hall, New York, 1993
Kent (2002) Genome Res 12: 656—664
Langmead et al (2009) Genome Biol 10:R25
Li and Durbin (2010) Bionformatics 26:589—595
—46-
Mitchell & Perfect (1995) al Microbiology Reviews 8(4):515—48)
Patterson et al. (2000) Medicine 79(4):250—60
Richer (1987) Pestic Sci 19:309-315
Sagaram et al., (2011) PLoS One 6.4: e18550
Singh et al. (2014) Journal of Oral and Maxillofacial ogy I8(Supp]):SSl—SS5
Supparatpinyo et al. (1996) Lancet 344(8915): 1 10—3
Thianprasit et al. (1996) Current Topics in l Mycology 7(1):43—54
Thomas (2003) Eye (London, d) I 7(8)2853—62
US Patent No. 6,911,577 (Pioneer Hi—Bred International, Inc. and BI. DuPont DeNemours
and Company)
Wanachiwanawin et al. (2004) Vaccine 22(27—28):3613—21
van der Weerden et al. (2013) Cell Mol Life Sci 70(19) 3545—3570
van der Weerden et al. (2013) Fungal Biol Rev 26: 121—131
Vibhagool et al. (2003) Clinical Infectious Diseases 36(10):1329—31
Claims (18)
1. A method for inhibiting infection of a microorganism on or in in vivo tissue in or on a non-human animal subject, said method comprising contacting the microorganism or tissue comprising the microorganism or administering to the subject an effective amount of plant defensin selected from SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 or a functional natural or synthetic derivative or t f or a defensin having at least 80% similarity to any one of SEQ ID NO:1,SEQ ID NO:2 and SEQ ID NO:3, after l alignment for a time and under conditions sufficient to ameliorate symptoms of the infection, wherein the microorganism is Candida spp., and wherein the in vivo tissue is mucosal or epithelial internal .
2. The method of Claim 1, wherein the infection of the mucosal or epithelial al tissue or a subcutaneous layer of skin is oral or vaginal thrush. .
3. The method of Claim 1 or Claim 2, wherein the defensin is defined by the consensus amino acid sequence SEQ ID NO:24.
4. The method of any one of Claims 1 to 3, wherein the defensin comprises an N- terminal e.
5. The method of Claim 4, n a defensin with an N-terminal alanine is selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:27.
6. The method of any one of Claims 1 to 5, wherein the defensin is used in combination with an antimicrobial agent.
7. The method of any one of Claims 1 to 6, wherein the antimicrobial agent is a peptide of from about 0.4 to about 12 kD or a proteinase inhibitor.
8. A l coating for a medical device or condom comprising a plant defensin selected from SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, or a functional natural or synthetic derivative or variant thereof or a defensin having at least 80% rity to any one of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 after optimal alignment.
9. The topical coating of Claim 8, wherein the defensin is defined by the consensus amino acid sequence SEQ ID NO:24.
10. The topical coating of Claim 8 or Claim 9, n the defensin comprises an N-terminal e.
11. The topical coating of Claim 10, wherein a defensin is selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:27.
12. Use of a plant defensin ed from SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, or a functional natural or synthetic derivative or variant thereof or a defensin having at least 80% similarity to any of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 after optimal ent in the manufacture of a medicament for the treatment or prophylaxis of microbial infection on or in an in vivo tissue in a human subject, wherein the microbial infection is a Candida spp. infection and wherein the in vivo tissue is l or epithelial internal tissue.
13. The use of Claim 12, wherein the defensin is defined by the consensus amino acid sequence SEQ ID NO:24.
14. The use of Claim 12 or Claim 13, wherein the defensin comprises an N- terminal alanine.
15. The use of Claim 14, wherein a defensin is selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:27.
16. The use of any one of Claims 12 to 15, wherein the defensin is formulated for administration in combination with an antimicrobial agent.
17. The use of any one of Claims 12 to 16, wherein the antimicrobial agent is a peptide of from about 0.4 to about 12 kD or a proteinase inhibitor.
18. The use of any one of Claims 13 to 17, wherein the defensin is formulated for g onto a medical device or condom.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/AU2015/050294 WO2016191790A1 (en) | 2015-05-29 | 2015-05-29 | A method of in vivo treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ736735A NZ736735A (en) | 2021-03-26 |
NZ736735B2 true NZ736735B2 (en) | 2021-06-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7267251B2 (en) | Antibacterial and pharmaceutical compositions | |
US11446354B2 (en) | Method of treatment | |
Wu et al. | Interaction of antimicrobial peptide s-thanatin with lipopolysaccharide in vitro and in an experimental mouse model of septic shock caused by a multidrug-resistant clinical isolate of Escherichia coli | |
Liu et al. | Fatty acid modified-antimicrobial peptide analogues with potent antimicrobial activity and topical therapeutic efficacy against Staphylococcus hyicus | |
CN109996554A (en) | Novel antimicrobial and anti-cancer therapies | |
AU2015396744B2 (en) | A method of in vivo treatment | |
NZ736735B2 (en) | A method of in vivo treatment | |
Kollu et al. | Soft tissue infection of the forearm with Scedosporium apiospermum complex and Neisseria spp. following a dog bite | |
NL2025294B1 (en) | Antimicrobial peptide for treatment and controlling virus infections | |
EP4352083A1 (en) | Short antimicrobial peptides | |
Acton | Antimicrobial Cationic Peptides—Advances in Research and Application: 2012 Edition | |
JP2024521385A (en) | Short antimicrobial peptides |